ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1738

Detect Outperforms Echocardiography Based Screening Guidelines for Early Detection of Systemic Sclerosis Associated Pulmonary Arterial Hypertension

Amber Young1, Victor M. Moles2,3, Vivek Nagaraja1, Dharshan Vummidi4, Scott H. Visovatti3, Vallerie McLaughlin3 and Dinesh Khanna1, 1Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, 2Hospital Jose Maria Cullen, Santa Fe, Argentina, 3Division of Cardiology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, 4Department of Radiology, University of Michigan, Ann Arbor, MI

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Systemic Sclerosis and Related Disorders – Clinical Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Pulmonary arterial hypertension (PAH) is a leading cause of mortality in patients with systemic sclerosis (SSc). Active screening can detect SSc-PAH earlier and may improve survival. Various screening algorithms and guidelines are currently used. Our objective was to compare the DETECT evidence based screening algorithm to the 2015 ESC/ERS consensus based guidelines.

Methods: Subjects with a diagnosis of SSc based on the 2013 ACR/EULAR criteria who did not have a prior diagnosis of pulmonary hypertension (PH) and underwent a right heart catheterization (RHC) due to increased risk based on 2013 recommendations for screening and detection of connective tissue disease-PAH and/or DETECT were evaluated. Retrospective review of those subjects was performed to identify subjects who had variables available for calculation of DETECT and also echocardiographic imaging available for application of 2015 ESC/ERS.

Results: Fifty-one subjects had no PH (mPAP < 25mmHg) or PAH (mPAP ≥ 25mmHg, PCWP ≤ 15mmHg, PVR > 3 WU) based on RHC and had variables available for retrospective application of DETECT (without strict application of inclusion/exclusion criteria) and 2015 ESC/ERS guidelines. Eighty-two percent were female and 61% had limited cutaneous SSc. Mean (SD) age was 59.5 (12.9) years old, disease duration was 8.5 (8.1) years, FVC% predicted was 81.7 (18.0), DLCO % predicted was 53.1 (17.6), and FVC/DLCO was 1.70 (0.67). Forty subjects had no PH and 11 subjects had PAH. DETECT had 100% sensitivity and NPV whereas 2015 ESC/ERS had 54.5% sensitivity and 82.8% NPV as 5 subjects with PAH were missed (Figure 1). DETECT was able to detect PAH even in those with DLCO ≥ 60% (N=3).

Conclusion: Evidence based screening algorithms using composite measures and not just echocardiography alone improve screening for SSc-PAH. Although use of DLCO < 60% enriches the probability for SSc-PAH, subjects with SSc-PAH can have higher DLCO values. Although our sample size is small, it appears that DETECT performs well in those with DLCO ≥ 60%.


Disclosure: A. Young, None; V. M. Moles, None; V. Nagaraja, None; D. Vummidi, Boehringer Ingelheim, 5; S. H. Visovatti, None; V. McLaughlin, Consultancies Bayer, Arena, Medtronic, Merck, SteadyMed, United Therapeutics, St. Jude Medical, Actelion., 5,Grant / Research Support: Actelion, Eiger, Sonovie, Arena, Bayer,, 2; D. Khanna, Eicos Sciences, 1,Pfizer, Inc., 2,Horizon, 2,BMS, 2,Actelion, 5,Bayer, 5,Bayer, 2,Corbus, 5,Cytori, 5,EMD Serono, 5,Genentech, Inc., 5,Sanofi-Aventis, 5,GSK, 5,Boehringer Ingelheim, 5,CiVi BioPharma, 3.

To cite this abstract in AMA style:

Young A, Moles VM, Nagaraja V, Vummidi D, Visovatti SH, McLaughlin V, Khanna D. Detect Outperforms Echocardiography Based Screening Guidelines for Early Detection of Systemic Sclerosis Associated Pulmonary Arterial Hypertension [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/detect-outperforms-echocardiography-based-screening-guidelines-for-early-detection-of-systemic-sclerosis-associated-pulmonary-arterial-hypertension/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/detect-outperforms-echocardiography-based-screening-guidelines-for-early-detection-of-systemic-sclerosis-associated-pulmonary-arterial-hypertension/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology